For site information, send an email with site number to
Investigational Site Number :2031003(0.9 mi away)Contact
+30 other location
Accepts healthy volunteers
Primary objective is to demonstrate the non-inferiority of the antibody response against
meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of
MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine
when each vaccine is given concomitantly with routine pediatric vaccines (10-valent
pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and
Haemophilus influenzae type b [DTaP-IPV-HB-Hib vaccine]) to infants and toddlers 6 weeks to
18 months old
Secondary objectives are:
To demonstrate the non-inferiority of the antibody (Ab) response against meningococcal
serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW
conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each
vaccine is given concomitantly with routine pediatric vaccines (10-valent pneumococcal
vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old.
To describe the Ab responses against meningococcal groups A, C, Y, and W and the
antigens of the routine pediatric vaccines administered in the study.
MenACYW conjugate vaccine,
Pneumococcal vaccine (13-valent),
Pneumococcal vaccine (10-valent),
Meningococcal group A, C, W-135, and Y conjugate vaccine
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.